Incobotulinum toxin A in Parkinson's disease with foot dystonia: A double blind randomized trial

• DOI: 10.1016/j.parkreldis.2017.10.009
• Publication Date: 2017-10-19T17:46:14Z
• Authors: Isabelle Rieu; Bertrand Degos; Giovanni Castelnovo; Christophe Vial; Elodie Durand; Bruno Pereira; Marion Simonetta-...; Sophie Sangla; Frédérique Fluchère; Dominique Guehl; Pierre Burbaud; Christian Geny; Dominique Gayraud; Fabienne Ory-Magne; Françoise Bouhour; Elisabeth Llinares; Philippe Derost; Ana Marques; Franck Durif
• Keywords: Male; [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior; [SCCO.NEUR]Cognitive science/Neuroscience; [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology; [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences; Forefoot, Human; Parkinson Disease; Middle Aged; 3. Good health; Dystonia; 03 medical and health sciences; 0302 clinical medicine; Double-Blind Method; Neuromuscular Agents; Outcome Assessment, Health Care; Humans; Female; Botulinum Toxins, Type A; Muscle, Skeletal; Aged

Plantar flexion of toe dystonia is very painful and leads to difficulties in walking. The objective of this study was to investigate the effect of incobotulinum toxin A (Xeomin) in the treatment of this type of dystonia in parkinsonian patients, using a randomized, double blind, placebo-controlled trial.45 parkinsonian patients with painful dystonic plantar flexion of toes were injected either with incobotulinum toxin A (Btx group), or with placebo in two muscle targets: the Flexor digitorum longus and the Flexor digitorum brevis. Three groups were compared: the first group received placebo in the Flexor digitorum longus and 100UI of Btx in the Flexor digitorum brevis (n = 16); the second group received 100 UI of Btx in the Flexor digitorum longus and placebo in the Flexor digitorum brevis (n = 13); and the third group, 2 injections of placebo (n = 16). The patients were injected in the same way twice with an interval of 3 months. The primary endpoint was measured six weeks after injections with the Clinical Global Impression (CGI) of change. Dystonia severity and associated pain were also assessed.Mean CGI was improved in the Btx group compared to the placebo group (P = 0.039). A significant reduction of pain and dystonia severity were observed in patients treated with Btx compared to baseline but no improvement was noted when compared to placebo group. No difference of efficacy was highlighted between the two injection sites.Btx injections are effective for improving clinical state of parkinsonian patients with plantar flexion of toe dystonia.